A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patients

Clinical Cancer Research

Volumn 15, Issue 10, 2009, Pages 3633-3639

  Schmitt, Antonin ^a   Gladieff, Laurence ^a   Lansiaux, Amélie ^b   Bobin Dubigeon, Christine ^c   Etienne Grimaldi, Marie Christine ^d   Boisdron Celle, Michèle ^e   Serre Debauvais, Françoise ^f   Pinguet, Frédéric ^g   Floquet, Anne ^h   Billaud, Eliane ⁱ   Le Guellec, Chantal ^j   Penel, Nicolas ^b   Campone, Mario ^c   Largillier, Rémy ^d   Capitain, Olivier ^e   Fabbro, Michel ^g   Houede, Nadine ^h   Medioni, Jacques ⁱ   Bougnoux, Philippe ^j   Lochon, Isabelle ^a   Chatelut, Etienne ^a,k   more..

^a UNIVERSITÉ DE TOULOUSE   (France)

^b CENTRE OSCAR LAMBRET   (France)

^c CENTRE RENÉ GAUDUCHEAU   (France)

^d CENTRE ANTOINE LACASSAGNE   (France)

^e CENTRE PAUL PAPIN   (France)

^f GRENOBLE UNIVERSITY HOSPITAL   (France)

^g CENTRE VAL D AURELLE   (France)

^h INSTITUT BERGONIÉ   (France)

ⁱ HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^j UNIVERSITY HOSPITAL OF TOURS   (France)

^k INSTITUT CLAUDIUS REGAUD   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYSTATIN C; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; NAVELBINE; PACLITAXEL;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BODY MASS; BODY WEIGHT; CANCER PATIENT; CLINICAL TRIAL; COMPUTER PROGRAM; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; HUMAN; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; MULTICENTER STUDY; OBESITY; PREDICTION; PRIORITY JOURNAL; SEX DIFFERENCE; UNDERWEIGHT;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS; BODY MASS INDEX; BODY WEIGHT; CARBOPLATIN; CYSTATIN C; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOASSAY; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASMS; OBESITY; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 66149190687     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-0017     Document Type: Article

References (24)

1. Duffull SB, Robinson BA. Clinical pharmacokinetics and dose optimisation of carboplatin. Clin Pharmacokinet 1997;33:161-183 (Pubitemid 27399545)
2. Egorin MJ, Van Echo DA, Olman EA, et al. Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutanedicarboxylatoplatinum. Cancer Res 1985;45:6502-6506 (Pubitemid 16224834)
3. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748-1756 (Pubitemid 19272848)
4. Cockcroft D, Gault M. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
5. Ekhart C, de Jonge ME, Huitema AD, et al. Flat dosing of carboplatin is justified in adult patients with normal renal function. Clin Cancer Res 2006;12:6502-6508
6. Herrington JD, Tran HT, Riggs MW. Prospective evaluation of carboplatin AUC dosing in patients with a BMI>or = 27 or cachexia. Cancer Chemother Pharmacol 2006;57:241-247 (Pubitemid 41779844)
7. Thomas F, Seronie-Vivien S, Gladieff L, et al. Cystatin C as a new covariate to predict renal elimination of drugs: application to carboplatin. Clin Pharmacokinet 2005;44:1305-1316 (Pubitemid 41832571)
8. Chatelut E, Canal P, Brunner V, et al. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 1995;87:573-580
9. Chatelut E, Pivot X, Otto J, et al. A limited sampling strategy for determining carboplatin AUC and monitoring drug dosage. Eur J Cancer 2000;36:264-269 (Pubitemid 30102205)
10. LeRoy AF, Wehling ML, Sponseller HL, et al. Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry. Biochem Med 1977;18:184-191 (Pubitemid 8213839)
11. Leger F, Seronie-Vivien S, Makdessi J, et al. Impact of the biochemical assay for serum creatinine measurement on the individual carboplatin dosing: a prospective study. Eur J Cancer 2002; 38:52-56 (Pubitemid 34031825)
12. World Health Organization. Report of a WHO consultation on Obesity: Preventing and Managing the Global Epidemic 1998.
13. Ando M, Minami H, Ando Y, et al. Multiinstitutional validation study of carboplatin dosing formula using adjusted serum creatinine level. Clin Cancer Res 2000;6:4733-4738 (Pubitemid 32110412)
14. Huitema AD, Mathot RA, Tibben MM, et al. Validation of techniques for the prediction of carboplatin exposure: application of Bayesian methods. Clin Pharmacol Ther 2000;67:621-630 (Pubitemid 30416078)
15. Nannan P, van Warmerdam V, Huizing LJ, et al. Carboplatin dosage formulae can generate inaccurate predictions of Carboplatin exposure in carboplatin/paclitaxel combination regimens. Clin Drug Investig 1998;15:327-335 (Pubitemid 28204007)
16. Okamoto H, Nagatomo A, Kunitoh H, Kunikane H, Watanabe K. Prediction of carboplatin clearance calculated by patient characteristics or 24- hour creatinine clearance: a comparison of the performance of three formulae. Cancer Chemother Pharmacol 1998;42:307-312 (Pubitemid 28393848)
17. van Warmerdam LJ, Rodenhuis S, Bokkel Huinink WW, Maes RA, Beijnen JH. Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatin. Cancer Chemother Pharmacol 1996;37:266-270
18. Jelliffe RW. Letter: Creatinine clearance: bedside estimate. Ann Intern Med 1973;79:604-605
19. Wright JG, Boddy AV, Highley M, et al. Estimation of glomerular filtration rate in cancer patients. Br J Cancer 2001;84:452-459 (Pubitemid 32215868)
20. Seronie-Vivien S, Galteau MM, Carlier MC, et al. [Improving the interlaboratory variation for creatinine serum assay]. Ann Biol Clin (Paris) 2004;62:165-175
21. Newman DJ. Cystatin C. Ann Clin Biochem 2002;39:89-104.
22. Hossain MA, Emara M, El Moselhi H, Shoker A. Comparing measures of cystatin c in human sera by three methods. Am J Nephrol 2008;29: 381-391
23. Hoppe A, Seronie-Vivien S, Thomas F, et al. Serum cystatin C is a better marker of topotecan clearance than serum creatinine. Clin Cancer Res 2005;11:3038-3044 (Pubitemid 40525210)
24. Hermida J, Tutor JC. Serum cystatin C for the prediction of glomerular filtration rate with regard to the dose adjustment of amikacin, gentamicin, tobramycin, and vancomycin. Ther Drug Monit 2006;28:326-331 (Pubitemid 44314918)